Key facts
- This page summarizes Goran Ando's Form 4 filing for EyePoint Pharmaceuticals, Inc. (EYPT).
- 2 reported transactions and 2 derivative rows are listed below.
- Filing timestamp: 22 Jun 2023, 09:19.
Goran Ando - 20 Jun 2023 Form 4 Insider Report for EyePoint Pharmaceuticals, Inc. (EYPT)
- Role
- Director
- Signature
- /s/ Ron Honig, Attorney-in-Fact
- Issuer symbol
- EYPT
- Transactions as of
- 20 Jun 2023
- Net transaction value
- $0
- Form type
- 4
- Filing time
- 22 Jun 2023, 09:19:25 UTC
- Previous filing
- 13 Feb 2023
- Next filing
- 09 Jan 2024
- SEC filing
- View on sec.gov
Reporting owner
Issuer context
Transaction snapshot
SEC evidence
Key filing fact
Goran Ando filed Form 4 for EyePoint Pharmaceuticals, Inc. (EYPT) on 22 Jun 2023.
Change
- Previous filing in this sequence was filed on 13 Feb 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
See Original Filing
Ownership activity is grounded in SEC Form 4 disclosures.
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
EYPT
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +27,100
- Change %
- Price
- $0.000000
- Shares after
- 27,100
- Date
- 20 Jun 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 27,100
- Exercise price
- $3.26
EYPT
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +13,500
- Change %
- Price
- $0.000000
- Shares after
- 13,500
- Date
- 20 Jun 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 13,500
- Exercise price
- $3.50
* indicates a reported price that failed the local validity check.